Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of treatment interruption on safety and efficacy of exenatide in type 2 diabetes
2006-006149-15Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, single-arm trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Primary endpoints: Treatment-emergent anti-exenatide antibody titre and Relationship of antibodies to adverse events (allergy and hypersensitivity). Started Mar 2007; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-006149-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006149-15.